725 Phase I safety and preliminary efficacy of PM8002 in subjects with advanced solid tumors, a bispecific antibody targeting PD-L1 and VEGF-A

Abstract

BackgroundPD-L1 and VEGF play important roles in immune escape and tumor angiogenesis and thus enhance cancer growth and metastasis. PM8002 is a bispecific antibody targeting PD-L1 and VEGF-A. Here we...